The therapeutic potential of 4-1BB (CD137) in cancer

被引：18

作者：

Nam, KO

Kang, WJ

Kwon, BS

Kim, SJ

Lee, HW ^{[1
]}

机构：

[1] Kyung Hee Univ, Dept Pharmacol, Sch Dent, Seoul 130701, South Korea

[2] Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea

来源：

CURRENT CANCER DRUG TARGETS | 2005年 / 5卷 / 05期

关键词：

4-1BB; CD8(+) T cells; cancer; signaling pathways;

D O I：

10.2174/1568009054629681

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-IBB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-IBB. Crosslinking of 4-IBB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-IBB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.

引用

页码：357 / 363

页数：7

共 85 条

[1]

Abbas A.K., 2003, CELLULAR MOL IMMUNOL, P298

[2] 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB [J].